Passage Bio Inc expected to post a loss of 89  cents a share - Earnings Preview

Passage Bio

29/04/2022 17:49

* Passage Bio Inc  PASG.OQ   PASG.O  is expected to show no
change
in quarterly revenue when it reports  results on May 3
(estimated). 
    * ​Refinitiv's mean analyst estimate for Passage Bio Inc is
for a
loss of 89 cents per share. For the same quarter last year, the
company reported a loss of 76 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Passage Bio
Inc
is $16​, above​ its last closing price of $2.00. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.90       -0.89      -0.95     Missed  -7.2
 Sep. 30 2021  -0.89       -0.86      -0.87     Missed  -1
 Jun. 30 2021  -0.76       -0.76      -0.90     Missed  -18.9​
 Mar. 31 2021  -0.75       -0.74      -0.76     Missed  -2.2
 ​​Dec.        -0.69       -0.70      -0.85     Missed  -21
 31 2020                                                
 Sep. 30 2020  -0.78       -0.76      -0.63     Beat    17.1​
 Jun. 30 2020  -0.57       -0.57      -0.60     Missed  -5.3
 Mar. 31 2020  -0.45       -0.45      -1.00     Missed  -123.9
 This summary was machine generated April 29 at 16:49 GMT.  All
figures in US dollars  unless otherwise stated